Literature DB >> 24145579

Icaritin reverses multidrug resistance of HepG2/ADR human hepatoma cells via downregulation of MDR1 and P‑glycoprotein expression.

Li Sun1, Weigang Chen, Lili Qu, Jie Wu, Jin Si.   

Abstract

Multidrug resistance (MDR) of tumor cells is a serious obstacle encountered in cancer treatment. In the current study a multiple drug‑resistant HepG2/adriamycin (HepG2/ADR) cell line was established and its MDR was characterized. Icaritin, an active ingredient isolated from the medical plant Herba Epimedium, was observed to reverse MDR in the present model. Icaritin significantly increased the intracellular accumulation of ADR and decreased the expression of the MDR1 gene in HepG2/ADR cells compared with drug‑sensitive HepG2 cells. In addition, the present results showed that icaritin may significantly downregulate the expression of P‑glycoprotein. These results indicate that icaritin is a novel and potent MDR reversal agent and may be a promising drug for tumor chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24145579     DOI: 10.3892/mmr.2013.1742

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  21 in total

1.  Icaritin activates JNK-dependent mPTP necrosis pathway in colorectal cancer cells.

Authors:  Chunxian Zhou; Zhengrong Chen; Xingsheng Lu; Hao Wu; Qunying Yang; Dongfeng Xu
Journal:  Tumour Biol       Date:  2015-10-01

2.  Icaritin induces apoptotic and autophagic cell death in human glioblastoma cells.

Authors:  Zhaopei Li; Xiangwen Meng; Lin Jin
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

3.  The nutritional herb Epimedium grandiflorum inhibits the growth in a model for the Luminal A molecular subtype of breast cancer.

Authors:  Nitin T Telang; Gou Li; Meena Katdare; Daniel W Sepkovic; H Leon Bradlow; George Y C Wong
Journal:  Oncol Lett       Date:  2017-02-13       Impact factor: 2.967

Review 4.  Multidrug-resistant cancer cells and cancer stem cells hijack cellular systems to circumvent systemic therapies, can natural products reverse this?

Authors:  Qian Zhang; Yunjiang Feng; Derek Kennedy
Journal:  Cell Mol Life Sci       Date:  2016-09-12       Impact factor: 9.261

5.  Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity.

Authors:  Juan Pablo Rigalli; Nadia Ciriaci; Agostina Arias; María Paula Ceballos; Silvina Stella Maris Villanueva; Marcelo Gabriel Luquita; Aldo Domingo Mottino; Carolina Inés Ghanem; Viviana Alicia Catania; María Laura Ruiz
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

6.  Synthesis of icariin from kaempferol through regioselective methylation and para-Claisen-Cope rearrangement.

Authors:  Qinggang Mei; Chun Wang; Zhigang Zhao; Weicheng Yuan; Guolin Zhang
Journal:  Beilstein J Org Chem       Date:  2015-07-20       Impact factor: 2.883

Review 7.  P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review.

Authors:  Hossam M Abdallah; Ahmed M Al-Abd; Riham Salah El-Dine; Ali M El-Halawany
Journal:  J Adv Res       Date:  2014-12-01       Impact factor: 10.479

8.  Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cells.

Authors:  Pei-Hua Lu; Min-Bin Chen; Yuan-Yuan Liu; Mian-Hua Wu; Wen-Ting Li; Mu-Xin Wei; Chao-Ying Liu; Shu-Kui Qin
Journal:  Oncotarget       Date:  2017-04-04

9.  Cytotoxic effect of icaritin and its mechanisms in inducing apoptosis in human burkitt lymphoma cell line.

Authors:  Zi-Jian Li; Can Yao; Su-Fang Liu; Long Chen; Ya-Ming Xi; Wen Zhang; Guang-Sen Zhang
Journal:  Biomed Res Int       Date:  2014-05-07       Impact factor: 3.411

Review 10.  Anti-Cancer Properties of the Naturally Occurring Aphrodisiacs: Icariin and Its Derivatives.

Authors:  Hui-Li Tan; Kok-Gan Chan; Priyia Pusparajah; Surasak Saokaew; Acharaporn Duangjai; Learn-Han Lee; Bey-Hing Goh
Journal:  Front Pharmacol       Date:  2016-06-29       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.